At week @ , patients achieving @ % or more improvement from baseline Psoriasis Area and Severity Index score ( PASI @ ) were rerandomized to @ dose levels of secukinumab retreatment as needed ( n = @ , @ mg ; n = @ , @ mg ) or fixed interval ( n = @ ; n = @ ) .